Skip to content

Amylyx Pharmaceuticals

US · AMLX #2392 by market cap Listed 2022
26.02 -0.18 -0.69%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 5.17 In line with history 65th percentile
5-year average 4.48 · #55 of 68 in Drug Manufacturers - Specialty & Generic
P/E ratio -21.18 Cheap vs history 3rd percentile
5-year average 23.86 · forward -22.39
P/S ratio -5,855.90 Cheap vs history 3rd percentile
5-year average -516.58 · forward 319.12

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Amylyx Pharmaceuticals (AMLX) 3.35B -18.20 4.44 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value24.50 Economic moatNone UncertaintyVery High

Trading 5.8% above Morningstar's fair value estimate.

Fair value

Amylyx Pharmaceuticals Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 24% premium over our quantitative fair value estimate of $24.50 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.

The company's lack of profitability decreases our estimated fair value. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of -3.9%, which ranks in the bottom 20% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are expensive.

The firm's liquidity is an additional cause for concern. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, for example, lies in the top 30% globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. This characteristic further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.

Amylyx Pharmaceuticals discussion 0 comments

Add a comment